Metraipolis › archive › dc_df7fe357bc0c

Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological… — Europe PMC PMID:36256604

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36256604
DOI
10.1371/journal.pone.0276107
License (as archived)
CC0-1.0
Archived
2026-10-16T06:40:30.604Z
SHA-256 of the archived text
0cb73a7be1c059b079b74d6c4224d0e8bb5fbb9ca50ee215d669992217c988d9
Stable URL of this page
https://metraipolis.com/documento/dc_df7fe357bc0c

How to cite

Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological… — Europe PMC PMID:36256604 — Europe PMC (en), https://europepmc.org/article/MED/36256604 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_df7fe357bc0c (Metraipolis archive dc_df7fe357bc0c, sha256 0cb73a7be1c059b079b74d6c4224d0e8bb5fbb9ca50ee215d669992217c988d9)
BibTeX
@misc{dcdf7fe357bc0c,
  title = {Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological… — Europe PMC PMID:36256604},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36256604},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_df7fe357bc0c; sha256 0cb73a7be1c059b079b74d6c4224d0e8bb5fbb9ca50ee215d669992217c988d9},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36256604. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The blood-brain barrier (BBB) presents a major obstacle in developing specific diagnostic imaging agents for many neurological disorders. In this study we aimed to generate single domain anti-mouse transferrin receptor antibodies (anti-mTfR VHHs) to mediate BBB transcytosis as components of novel MRI molecular contrast imaging agents. Anti-mTfR VHHs were produced by immunizing a llama with mTfR, generation of a VHH phage display library, immunopanning, and in vitro characterization of candidates. Site directed mutagenesis was used to generate additional variants. VHH fusions with neurotensin (NT) allowed rapid, hypothermia-based screening for VHH-mediated BBB transcytosis in wild-type mice. One anti-mTfR VHH variant was fused with an anti-amyloid-beta (Aβ) VHH dimer and labeled with fluorescent dye for direct assessment of in vivo target engagement in a mouse model of AD-related Aβ plaque pathology. An anti-mTfR VHH called M1 and variants had binding affinities to mTfR of <1nM to 1.52nM. The affinity of the VHH binding to mTfR correlated with the efficiency of the VHH-NT induced hypothermia effects after intravenous injection of 600 nmol/kg body weight, ranging from undetectable for nonbinding mutants to -6°C for the best mutants. The anti-mTfR VHH variant M1P96H with the strongest hypothermia effect was fused to the anti-Aβ VHH dimer and labeled with Alexa647; the dye-labeled VHH fusion construct still bound both mTfR and Aβ plaques at concentrations as low as 0.22 nM. However, after intravenous injection at 600 nmol/kg body weight into APP/PS1 transgenic mice, there was no detectible labeling of plaques above control levels. Thus, NT-induced hypothermia did not correlate with direct target engagement in cortex, likely because the concentration required for NT-induced hypothermia was lower than the concentration required to produce in situ labeling. These findings reveal an important dissociation between NT-induced hypothermia, presumably mediated by hypothalamus, and direct engagement with Aβ-plaques in cortex. Additional methods to assess anti-mTfR VHH BBB transcytosis will need to be developed for anti-mTfR VHH screening and the development of novel MRI molecular contrast agents.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-10-18).
Identificativi: PMID 36256604 · PMCID PMC9578589 · DOI 10.1371/journal.pone.0276107.
Descrittori MeSH principali: Camelids, New World; Alzheimer Disease; Hypothermia.
Pagina: https://europepmc.org/article/MED/36256604 — https://doi.org/10.1371/journal.pone.0276107. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-16T06:20:18.899Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.